• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

LUMIRACOXIB Drug Record

  • Summary
  • Interactions
  • Claims
  • LUMIRACOXIB chembl:CHEMBL404108

    Alternate Names:

    PREXIGE
    LUMIRACOXIB
    COX-189
    PREXIGE®
    LUMIRACOXIBUM
    COX 189
    2-((2-CHLORO-6-FLUOROPHENYL)AMINO)-5-METHYLBENZENEACETIC ACID
    COX189
    drugbank:01283
    pubchem.compound:151166
    chembl:CHEMBL404108
    chemidplus:220991-20-8

    Drug Info:

    Year of Approval not approved by the fda
    Drug Class anti-inflammatory agent, selective cyclooxygenase 2 inhibitors
    FDA Approval not approved
    Drug Class Small Molecule
    Drug Indications NSAID
    (1 More Sources)

    Publications:

    Grosser T, 2009, Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy., J Investig Med
    Esser et al., 2005, Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2., Br. J. Pharmacol.
    Atherton et al., 2004, Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study., Clin. Gastroenterol. Hepatol.
    Capone et al., Clinical pharmacology of selective COX-2 inhibitors., Int J Immunopathol Pharmacol
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Kalbag et al., 2004, No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor., Pharmacol. Res.
    Tacconelli et al., 2004, Clinical pharmacology of novel selective COX-2 inhibitors., Curr. Pharm. Des.
    Singer JB et al., 2010, A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury., Nat Genet
  • LUMIRACOXIB   HLA-DQA1

    Interaction Score: 7.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20639878


    Sources:
    PharmGKB

  • LUMIRACOXIB   HLA-DQB1

    Interaction Score: 2.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20639878


    Sources:
    PharmGKB

  • LUMIRACOXIB   PTGS2

    Interaction Score: 2.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name lumiracoxib, COX 189,Prexige
    Novel drug target Established target

    PMIDs:
    19602986 15655513 15017615 14552704 11752352 15177307 14965322


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • LUMIRACOXIB   HLA-DRB1

    Interaction Score: 1.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20639878


    Sources:
    PharmGKB

  • TEND: LUMIRACOXIB

    • Version: 01-August-2011

    Alternate Names:
    LUMIRACOXIB Primary Drug Name

    Drug Info:
    Drug Class anti-inflammatory agent, selective cyclooxygenase 2 inhibitors
    Year of Approval not approved by the fda

    Publications:

  • TdgClinicalTrial: LUMIRACOXIB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications NSAID
    Drug Class Small Molecule
    FDA Approval not approved

    Publications:

  • PharmGKB: lumiracoxib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Grosser T, 2009, Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy., J Investig Med
    Singer JB et al., 2010, A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury., Nat Genet

  • TTD: Lumiracoxib

    • Version: 2020.06.01

    Alternate Names:
    D04YMH TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL404108

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21